Acura Pharmaceuticals, Inc. is a drug delivery company that is engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. The Company has discovered and developed approximately three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine tablets into methamphetamine.